Superficial and Deep Lymph Node Dissection for Stage III Cutaneous Melanoma: Clinical Outcome and Prognostic Factors

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2013 Feb 6

PMID 23379355

Citations 7

Authors

Nicola Mozzillo

Corrado Caraco

Ugo Marone

Gianluca Di Monta

Anna Crispo

Gerardo Botti

Maurizio Montella

Paolo Antonio Ascierto

Affiliations

Soon will be listed here.

Abstract

Background: The aims of this retrospective analysis were to evaluate the effect of combined superficial and deep groin dissection on disease-free and melanoma-specific survival, and to identify the most important factors for predicting the involvement of deep nodes according to clinically or microscopically detected nodal metastases.

Methods: Between January 1996 and December 2005, 133 consecutive patients with groin lymph node metastases underwent superficial and deep dissection at the National Cancer Institute, Naples. Lymph node involvement was clinically evident in 84 patients and detected by sentinel node biopsy in 49 cases.

Results: The 5-year disease-free survival was significantly better for patients with superficial lymph node metastases than for patients with involvement of both superficial and deep lymph nodes (34.9% vs. 19.0%; P = 0.001). The 5-year melanoma-specific survival was also significantly better for patients with superficial node metastases only (55.6% vs. 33.3%; P = 0.001).

Conclusions: Metastasis in the deep nodes is the strongest predictor of both disease-free and melanoma-specific survival. Deep groin dissection should be considered for all patients with groin clinical nodal involvement, but might be spared in patients with a positive sentinel node. Prospective studies will clarify the issue further.

Citing Articles

CT diagnosis of ilioinguinal lymph node metastases in melanoma using radiological characteristics beyond size and asymmetry.

Wilkinson M, Snow H, Downey K, Thomas K, Riddell A, Francis N BJS Open. 2021; 5(1).

PMID: 33609385 PMC: 7893466. DOI: 10.1093/bjsopen/zraa005.

Correlation of tumor-infiltrating immune cells of melanoma with overall survival by immunogenomic analysis.

Huang L, Chen H, Xu Y, Chen J, Liu Z, Xu Q Cancer Med. 2020; 9(22):8444-8456.

PMID: 32931642 PMC: 7666744. DOI: 10.1002/cam4.3466.

Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.

Dinnes J, Ferrante di Ruffano L, Takwoingi Y, Cheung S, Nathan P, Matin R Cochrane Database Syst Rev. 2019; 7:CD012806.

PMID: 31260100 PMC: 6601698. DOI: 10.1002/14651858.CD012806.pub2.

Optimal extent of completion lymphadenectomy for patients with melanoma and a positive sentinel node in the groin.

Verver D, Madu M, Oude Ophuis C, Faut M, de Wilt J, Bonenkamp J Br J Surg. 2017; 105(1):96-105.

PMID: 29095479 PMC: 5765473. DOI: 10.1002/bjs.10644.

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015.

Galon J, Fox B, Bifulco C, Masucci G, Rau T, Botti G J Transl Med. 2016; 14:273.

PMID: 27650038 PMC: 5029056. DOI: 10.1186/s12967-016-1029-z.

References

Poos H, Kruijff S, Bastiaannet E, van Ginkel R, Hoekstra H . Therapeutic groin dissection for melanoma: risk factors for short term morbidity. Eur J Surg Oncol. 2008; 35(8):877-83. DOI: 10.1016/j.ejso.2008.10.012. View

Sterne G, Murray D, Grimley R . Ilioinguinal block dissection for malignant melanoma. Br J Surg. 1995; 82(8):1057-9. DOI: 10.1002/bjs.1800820819. View

Rossi C, Mocellin S, Pasquali S, Pilati P, Nitti D . N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma. Ann Surg Oncol. 2007; 15(1):310-5. DOI: 10.1245/s10434-007-9641-z. View

Singletary S, Shallenberger R, GUINEE V . Surgical management of groin nodal metastases from primary melanoma of the lower extremity. Surg Gynecol Obstet. 1992; 174(3):195-200. View

Galliot-Repkat C, Cailliod R, Trost O, Danino A, Collet E, Lambert D . The prognostic impact of the extent of lymph node dissection in patients with stage III melanoma. Eur J Surg Oncol. 2006; 32(7):790-4. DOI: 10.1016/j.ejso.2006.04.004. View

Spillane A, Cheung B, Winstanley J, Thompson J . Lymph node ratio provides prognostic information in addition to american joint committee on cancer N stage in patients with melanoma, even if quality of surgery is standardized. Ann Surg. 2010; 253(1):109-15. DOI: 10.1097/SLA.0b013e3181f9b8b6. View

Kissin M, Simpson D, Easton D, White H, Westbury G . Prognostic factors related to survival and groin recurrence following therapeutic lymph node dissection for lower limb malignant melanoma. Br J Surg. 1987; 74(11):1023-6. DOI: 10.1002/bjs.1800741122. View

Xing Y, Badgwell B, Ross M, Gershenwald J, Lee J, Mansfield P . Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer. 2009; 115(11):2505-13. PMC: 2755291. DOI: 10.1002/cncr.24290. View

Coit D, Rogatko A, Brennan M . Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. Ann Surg. 1991; 214(5):627-36. PMC: 1358620. DOI: 10.1097/00000658-199111000-00014. View

10.

Coit D, Brennan M . Extent of lymph node dissection in melanoma of the trunk or lower extremity. Arch Surg. 1989; 124(2):162-6. DOI: 10.1001/archsurg.1989.01410020032004. View

11.

Balch C, Ross M . Melanoma patients with iliac nodal metastases can be cured. Ann Surg Oncol. 1999; 6(3):230-1. DOI: 10.1007/s10434-999-0230-1. View

12.

van der Ploeg A, van Akkooi A, Schmitz P, van Geel A, de Wilt J, Eggermont A . Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection. Ann Surg Oncol. 2011; 18(12):3300-8. PMC: 3192282. DOI: 10.1245/s10434-011-1741-0. View

13.

Badgwell B, Xing Y, Gershenwald J, Lee J, Mansfield P, Ross M . Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Ann Surg Oncol. 2007; 14(10):2867-75. DOI: 10.1245/s10434-007-9512-7. View

14.

van Akkooi A, Bouwhuis M, van Geel A, Hoedemaker R, Verhoef C, Grunhagen D . Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur J Surg Oncol. 2006; 33(1):102-8. DOI: 10.1016/j.ejso.2006.10.032. View

15.

Kretschmer L, Neumann C, Preusser K, Marsch W . Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin--an analysis of survival and local recurrence. Acta Oncol. 2001; 40(1):72-8. DOI: 10.1080/028418601750071091. View

16.

Urist M, Maddox W, Kennedy J, Balch C . Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients. Cancer. 1983; 51(11):2152-6. DOI: 10.1002/1097-0142(19830601)51:11<2152::aid-cncr2820511134>3.0.co;2-7. View

17.

Essner R, Scheri R, Kavanagh M, Torisu-Itakura H, Wanek L, Morton D . Surgical management of the groin lymph nodes in melanoma in the era of sentinel lymph node dissection. Arch Surg. 2006; 141(9):877-82. DOI: 10.1001/archsurg.141.9.877. View

18.

White R, Stanley W, Johnson J, Tyler D, Seigler H . Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg. 2002; 235(6):879-87. PMC: 1422519. DOI: 10.1097/00000658-200206000-00017. View

19.

Miranda E, Gertner M, Wall J, Grace E, Kashani-Sabet M, Allen R . Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg. 2004; 139(8):831-6. DOI: 10.1001/archsurg.139.8.831. View

20.

Hughes T, Thomas J . Combined inguinal and pelvic lymph node dissection for stage III melanoma. Br J Surg. 1999; 86(12):1493-8. DOI: 10.1046/j.1365-2168.1999.01316.x. View